Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $350
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Madrigal Pharmaceuticals but lowers the price target from $375 to $350.
October 23, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer's analyst Jay Olson continues to rate Madrigal Pharmaceuticals as Outperform, but reduces the price target from $375 to $350, indicating a slightly less optimistic outlook.
The maintained Outperform rating suggests continued confidence in Madrigal Pharmaceuticals' performance, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100